[
  {
    "variant_string_id": "EGFR L858R",
    "assessment": {
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses EGFR mutations, particularly L858R, as drivers of non-small cell lung cancer, leading to constitutive EGFR tyrosine kinase activity and uncontrolled cell proliferation.",
          "judgment": "Yes",
          "reasoning": "The paper establishes a clear link between EGFR mutations like L858R and cancer development through a well-defined molecular mechanism.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper employs an enzyme activity assay to assess the kinase activity of EGFR mutants, including L858R. Kinase activity assays are a common and generally accepted method for evaluating the effect of mutations on EGFR function in cancer.",
          "judgment": "Yes",
          "reasoning": "Kinase activity assays directly assess the functional impact of EGFR mutations on its core activity and is a well-established approach for evaluating disease-causing mutations.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The enzyme activity assay includes a wild-type EGFR control and a null mutant as a negative control. The experiment was repeated in triplicate.",
          "judgment": "Yes",
          "reasoning": "Both necessary control types (wild-type and null) were used and results were obtained with multiple replicates.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study utilized known pathogenic EGFR mutants as controls to compare activity with the L858R variant.  They did not include known benign variants.",
          "judgment": "Yes",
          "reasoning": "Pathogenic variants were used as controls, fulfilling one condition for proceeding to Step 4.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The paper provides quantitative data on kinase activity for EGFR L858R, compared with wild-type and other mutants, and performs statistical comparisons (p-values) to assess significance.",
          "judgment": "Yes",
          "reasoning": "Statistical analysis was performed to quantify differences in kinase activity.",
          "next_step_or_outcome": "Proceed to Sub-step 4c"
        },
        {
          "step_name": "Sub-step 4c: Correlate OddsPath",
          "extracted_paper_info": "Based on the provided data and comparisons, the kinase activity of EGFR L858R exhibits a statistically significant increase compared to wild-type EGFR (p<0.001).",
          "judgment": "N/A",
          "reasoning": "A direct OddsPath was not provided, but statistical significance was clearly demonstrated.",
          "next_step_or_outcome": "Apply the logic for when a direct OddsPath is not given."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The enzyme activity assay demonstrates significantly increased kinase activity for EGFR L858R compared to wild-type, consistent with its pathogenic role in lung cancer.  While a direct OddsPath value wasn't provided, the clear statistical significance supports a moderate level of pathogenicity."
    }
  }
]